Early quantification of the therapeutic efficacy of the vascular disrupting agent, CKD-516, using dynamic contrast-enhanced ultrasonography in rabbit VX2 liver tumors.
Ijin JooJung Hoon KimJeong Min LeeJin Woo ChoiJoon Koo HanByung Ihn ChoiPublished in: Ultrasonography (Seoul, Korea) (2013)
Our results suggest that a novel VDA (CKD-516) can cause disruption of tumor perfusion as early as two hours after treatment and that the therapeutic effect of CKD-516 treatment can be effectively quantified using DCE-US.